blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3959234

EP3959234 - CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  28.01.2022
Database last updated on 18.11.2024
FormerThe international publication has been made
Status updated on  31.10.2020
Formerunknown
Status updated on  22.05.2020
Most recent event   Tooltip19.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2022/09]
Inventor(s)01 / XUE, Wei
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
02 / CHEN, John
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
03 / SCOTT, Carolyn
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
04 / LONEY, Theodore
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
05 / GOLDEN, Nathaniel
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
 [2022/09]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/09]
Application number, filing date20725601.722.04.2020
[2022/09]
WO2020US29370
Priority number, dateUS201962837263P23.04.2019         Original published format: US 201962837263 P
[2022/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020219582
Date:29.10.2020
Language:EN
[2020/44]
Type: A1 Application with search report 
No.:EP3959234
Date:02.03.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 29.10.2020 takes the place of the publication of the European patent application.
[2022/09]
Search report(s)International search report - published on:EP29.10.2020
ClassificationIPC:C07K14/71, C12N5/00
[2022/09]
CPC:
C07K14/71 (EP,IL,KR); C12N5/0037 (IL,US); C12N5/0018 (EP,IL,KR);
C12N5/0043 (IL,US); C07K2319/30 (IL,KR,US); C12N2500/30 (IL,US);
C12N2500/38 (EP,IL,KR); C12N2500/40 (EP,IL,KR,US); C12N2500/46 (IL,US);
C12N2500/92 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/09]
TitleGerman:ZELLKULTURMEDIUM FÜR EUKARYOTISCHE ZELLEN[2022/09]
English:CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS[2022/09]
French:MILIEU DE CULTURE CELLULAIRE POUR CELLULES EUCARYOTES[2022/09]
Entry into regional phase23.11.2021National basic fee paid 
23.11.2021Designation fee(s) paid 
23.11.2021Examination fee paid 
Examination procedure23.11.2021Examination requested  [2022/09]
23.11.2021Date on which the examining division has become responsible
13.07.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
20.04.2022Renewal fee patent year 03
20.04.2023Renewal fee patent year 04
18.04.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XAI]WO2017024062  (REGENERON PHARMA [US]) [X] 1,3,6-11,28 * Serum-free medium to culture, e.g., CHO cells, BHK, 293, paragraph [0028]. Also paragraphs [0048], [00106] regarding aflibercept production (VEGF trap); paragraph [0023] - paragraph [0029] * * niacinamide (B3) containing culture media, and standard base media. Also paragraph [0060], serum free and chemically defined media. Example 1; pH set 7.0 +/- 0.15 or pH 7.13 +/- 0.27; paragraph [0071] - paragraph [0074]; example 1; claim 10 * * [00107], Examples of useful cells include BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, chicken embryo cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, Per.C6 cells and CHO cells.; paragraphs [0083] , [ 00107] * [A] 2 [I] 4,5,12-27;
 [XAI]EP3431588  (HOFFMANN LA ROCHE [CH]) [X] 1,3,8-11 * Serum-free mammalian cell culture medium Chemically defined (paragraph [0030]); paragraph [0002] - paragraph [0009] * * CHO host cells expressing an Apomab antibody, anti-VEGF antibody, and the fusion protein BR3-Fc, respectively were used.The host cells were adapted in suspension and serum free cultures. Commercially available DMEM/F12 culture medium contains niacinamide at 2.0185 mg/L pH medium used around 7.0; paragraphs [0215] , [ 0219] - paragraph [0238]; figures 7A, 7B; example 1; claim 9 * [A] 2 [I] 4,5,12-28;
 [XA]  - Todd M Bavarese ET AL, "Conversion of 5'-Deoxy-5'-methylthioadenosine and 5'-Deoxy-5'- methylthioinosine to Methionine in Cultured Human Leukemic Cells1", CANCER RESEARCH Williams General Hospital [ Biochemical Pharmacology [, (19831001), pages 4699 - 4702, URL: https://cancerres.aacrjournals.org/content/canres/43/10/4699.full.pdf, XP055707018 [X] 1-3,5-8 * page 4699, column 2, paragraph 4 - page 4670, column 2, paragraph 1 * [A] 4,9-28
by applicantUS6927004
 US7087411
 US7279159
    - DARIUS GHADERI et al., "Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, (20120000), vol. 28, doi:10.5661/bger-28-147, pages 147 - 176, XP055556640

DOI:   http://dx.doi.org/10.5661/bger-28-147
    - A. ASHKENAZI et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (19910000), vol. 88, doi:10.1073/pnas.88.23.10535, pages 10535 - 10539, XP002029642

DOI:   http://dx.doi.org/10.1073/pnas.88.23.10535
    - RANDAL A. BYRN et al., "Biological properties of a CD4 immunoadhesin", NATURE, (19900000), vol. 344, pages 667 - 670
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.